Cargando…

Leflunomide triggers synthetic lethality in PTEN-deficient prostate cancer

BACKGROUND: The loss of PTEN function presents in up to 50% of late-stage prostate cancers, and is therefore a potential target for therapeutics. PTEN-deficient cells depend on de novo pyrimidine synthesis, a feature which can present a vulnerability. METHODS: We utilized in vitro growth assays and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ozturk, Sait, Mathur, Deepti, Zhou, Royce W., Mulholland, David, Parsons, Ramon
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7666085/ https://www.ncbi.nlm.nih.gov/pubmed/32661432 http://dx.doi.org/10.1038/s41391-020-0251-1

Ejemplares similares

PARG deficiency is neither synthetic lethal with BRCA1 nor PTEN deficiency
por: Noll, Aurélia, et al.
Publicado: (2016)

Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors
por: Mendes-Pereira, Ana M, et al.
Publicado: (2009)

Synthetic lethal approaches to target cancers with loss of PTEN function
por: Ertay, Ayse, et al.
Publicado: (2023)

Synthetic lethality of a cell-penetrating anti-RAD51 antibody in PTEN-deficient melanoma and glioma cells
por: Turchick, Audrey, et al.
Publicado: (2019)

The PTEN Conundrum: How to Target PTEN-Deficient Prostate Cancer
por: Turnham, Daniel J., et al.
Publicado: (2020)

PTEN interacts with the transcription machinery on chromatin and regulates RNA polymerase II-mediated transcription
por: Steinbach, Nicole, et al.
Publicado: (2019)

Identification of Androgen Receptor Splice Variants in the Pten Deficient Murine Prostate Cancer Model
por: Liang, Mengmeng, et al.
Publicado: (2015)

Reactive Arthritis Triggered by Adalimumab and Leflunomide in a Patient with Ankylosing Spondylitis
por: Liu, Ying, et al.
Publicado: (2022)

Correction: Identification of Androgen Receptor Splice Variants in the Pten Deficient Murine Prostate Cancer Model
por: Liang, Mengmeng, et al.
Publicado: (2016)

Histone Acetyltransferase (HAT) P300/CBP Inhibitors Induce Synthetic Lethality in PTEN-Deficient Colorectal Cancer Cells through Destabilizing AKT
por: Liu, Yifan, et al.
Publicado: (2020)

Simultaneous Targeting of PARP1 and RAD52 Triggers Dual Synthetic Lethality in BRCA-Deficient Tumor Cells
por: Sullivan-Reed, Katherine, et al.
Publicado: (2018)

World Trade Center Dust Exposure Promotes Cancer in PTEN-deficient Mouse Prostates
por: Wang, Lin, et al.
Publicado: (2022)

AKT inhibition impairs PCNA ubiquitylation and triggers synthetic lethality in homologous recombination-deficient cells submitted to replication stress
por: Villafañez, Florencia, et al.
Publicado: (2019)

Inhibition of Pten deficient Castration Resistant Prostate Cancer by Targeting of the SET - PP2A Signaling axis
por: Hu, Xiaoyong, et al.
Publicado: (2015)

AKT activation because of PTEN loss upregulates xCT via GSK3β/NRF2, leading to inhibition of ferroptosis in PTEN-mutant tumor cells
por: Cahuzac, Kaitlyn M., et al.
Publicado: (2023)

Leflunomide-Induced Hidradenitis Suppurativa
por: Machan, Achraf, et al.
Publicado: (2020)

OGG1 Inhibition Triggers Synthetic Lethality and Enhances The Effect of PARP Inhibitor Olaparib in BRCA1-Deficient TNBC Cells
por: Baquero, Juan Miguel, et al.
Publicado: (2022)

Sirtuin inhibition is synthetic lethal with BRCA1 or BRCA2 deficiency
por: Bajrami, Ilirjana, et al.
Publicado: (2021)

Inhibition of Notch pathway arrests PTEN-deficient advanced prostate cancer by triggering p27-driven cellular senescence
por: Revandkar, Ajinkya, et al.
Publicado: (2016)

Modeling synthetic lethality
por: Le Meur, Nolwenn, et al.
Publicado: (2008)

MDM2 inhibition is synthetic lethal with PTEN loss in colorectal cancer cells via the p53-dependent mechanism
por: Ren, Guowen, et al.
Publicado: (2023)

Leflunomide leads to inhibition of transendothelial migration
por: Grisar, J, et al.
Publicado: (2001)

Deficiency of Pten accelerates mammary oncogenesis in MMTV-Wnt-1 transgenic mice
por: Li, Yi, et al.
Publicado: (2001)

Synthetic lethality between androgen receptor signalling and the PARP pathway in prostate cancer
por: Asim, Mohammad, et al.
Publicado: (2017)

Development of 'synthetic lethal' strategies to target BRCA1-deficient breast cancer
por: Wicha, Max S
Publicado: (2009)

Synthetic lethality of cytolytic HSV-1 in cancer cells with ATRX and PML deficiency
por: Han, Mingqi, et al.
Publicado: (2019)

VRK1 Is a Synthetic–Lethal Target in VRK2-Deficient Glioblastoma
por: Shields, Julie A., et al.
Publicado: (2022)

Leflunomide therapy for IgA vasculitis with nephritis in children
por: Hou, Ling, et al.
Publicado: (2021)

Leflunomide monotherapy versus combination therapy with conventional synthetic disease-modifying antirheumatic drugs for rheumatoid arthritis: a retrospective study
por: Deng, Daihua, et al.
Publicado: (2020)

DNA repair and synthetic lethality
por: Guo, Gong-she, et al.
Publicado: (2011)

Synthetic Lethality in Ovarian Cancer
por: Chandrasekaran, Akshaya, et al.
Publicado: (2021)

Amelioration of Experimental Autoimmune Uveitis by Leflunomide in Lewis Rats
por: Fang, Cheng-bo, et al.
Publicado: (2013)

The tumor therapy landscape of synthetic lethality
por: Zhang, Biyu, et al.
Publicado: (2021)

Cohesin mutations are synthetic lethal with stimulation of WNT signaling
por: Chin, Chue Vin, et al.
Publicado: (2020)

Use of leflunomide in patients with chronic hypersensitivity pneumonitis
por: Noh, Sungryong, et al.
Publicado: (2020)

8. Myositis as an idiosyncratic drug reaction to leflunomide
por: Darren, Angeline, et al.
Publicado: (2019)

ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A
por: Williamson, Chris T., et al.
Publicado: (2016)

STAG1 vulnerabilities for exploiting cohesin synthetic lethality in STAG2-deficient cancers
por: van der Lelij, Petra, et al.
Publicado: (2020)

Allosteric AKT Inhibitors Target Synthetic Lethal Vulnerabilities in E-Cadherin-Deficient Cells
por: Bougen-Zhukov, Nicola, et al.
Publicado: (2019)

Withaferin A Inhibits Prostate Carcinogenesis in a PTEN-deficient Mouse Model of Prostate Cancer()()
por: Moselhy, Jim, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_v0705ccv46e93hdqrfj1sg5vd9